The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12625001238460
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
23/10/2025
Date registered
Help: Date registered
6/11/2025
Date last updated
Help: Date last updated
13/12/2025
Date data sharing statement initially provided
Help: Data sharing statement date
6/11/2025
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Clinical Trial to investigate the feasibility, safety, and tolerability of BMS-986504 in patients with recurrent MTAP-deleted Glioblastoma
Scientific title
PRIME: A Phase 0/II open-label study of perioperative PRMT5 Inhibition with BMS-986504 in patients with recurrent MTAP-deleted glioblastoma
Additional trial identifiers [1] 315664 0
Nil known
Universal Trial Number (UTN)
Trial acronym
PRIME
Related trial records

Health condition
Health condition(s) studied:
Recurrent MTAP-deleted Glioblastoma 339348 0
Condition category
Condition code
Cancer 335603 335603 0 0
Brain

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants will receive the drug BMS-986504 prior to and following surgical resection of the glioblastoma cancer. Treatment given prior to surgery is referred to as ‘neoadjuvant treatment’. Treatment given after surgery is referred to as ‘adjuvant treatment’.

BMS-986504 Neoadjuvant treatment: oral tablet, 600mg once daily, administered continuously from Day 1 to 21 of Cycle 1 or from Day 1 to the day of surgical resection. Participants will be given a medication diary to record when doses are taken.

Surgical Resection: The treating neurosurgeon will perform surgery to remove the glioblastoma cancer. Surgical adjuncts (such as 5-aminolevulenic acid, intraoperative MRI, or awake surgery with cortical mapping) will be utilised. After the surgery participants will be monitored in the neurosurgery ward for a minimum of two days.

BMS-986504 Adjuvant treatment: oral tablet, 600mg once daily, administered continuously until disease progression, commencement of new anti-glioblastoma therapy or unacceptable toxicity. Participants will be evaluated at 3-weekly intervals to determine cessation or continuation of BMS-986504 adjuvant treatment. Participants will be given a medication diary to record when doses are taken.
Intervention code [1] 332276 0
Treatment: Drugs
Intervention code [2] 332277 0
Treatment: Surgery
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 343148 0
To assess the safety of undertaking a peri-operative study with BMS-986504 in patients with recurrent MTAP-deleted glioblastoma (GBM)
Timepoint [1] 343148 0
Adverse events will be assessed continuously from start of treatment until the Safety Follow-up visit for each patient, which will be 30 days after the last dose of treatment
Primary outcome [2] 343149 0
To assess the feasibility of undertaking a perioperative study with BMS-986504 in patients with recurrent MTAP-deleted GBM
Timepoint [2] 343149 0
From registration to the completion of surgical resection for each patient
Secondary outcome [1] 453523 0
To determine biological activity of BMS-986504 in patients with recurrent MTAP-deleted GBM
Timepoint [1] 453523 0
From enrollment to time of progression for each patient. Assessments will occur 8 weekly to determine time of progression
Secondary outcome [2] 453524 0
To determine the toxicity of BMS-986504 in patients with recurrent MTAP-deleted GBM following biopsy, and prior to surgery
Timepoint [2] 453524 0
From time of biopsy to time of surgical resection for each patient
Secondary outcome [3] 453525 0
To assess the pharmacokinetics (PK) of BMS-986504 post biopsy and prior to resection for patients with recurrent MTAP-deleted GBM
Timepoint [3] 453525 0
From time of biopsy to time of surgical resection for each patient
Secondary outcome [4] 453526 0
To determine the objective response to BMS-986504 in recurrent MTAP-deleted GBM
Timepoint [4] 453526 0
Response will be assessed 8 weekly from time of surgical resection to time of progression for each patient
Secondary outcome [5] 453527 0
To assess survival of patients with recurrent MTAP-deleted GBM receiving BMS-986504
Timepoint [5] 453527 0
Cumulative data for all outcomes will be assessed at the end of the study, approximately 36 months after first patient was registered

Eligibility
Key inclusion criteria
1. Patient has provided written informed consent using the PRIME Patient Information and Consent Form (PICF)
2. Histologically confirmed intracranial GBM per 2021 WHO classification guidelines
3. MTAP deficient tumours defined as evidence of homozygous deletion of one or more exons of the MTAP gene in tumour tissue AND/OR loss of MTAP expression in the tumour tissue
4. Adults greater than or equal to 18 years of age at the time of signing consent
5. Evidence of recurrent disease demonstrated by radiological progression
6. Patients must have received standard first line treatment for GBM, including Temozolomide (TMZ) and radiation therapy. Patients who are MGMT unmethylated do not need to have receive TMZ to be eligible, radiation alone is sufficient
7. Patients who in the opinion of the treating neurosurgeon require resection and suitable for two surgical procedures
8. Patient is willing to undergo planned surgical procedures
9. Eastern Co-operative Oncology Group (ECOG) performance status of 0-1
10. Minimum life expectancy of 6 months as per investigator judgement
11. Be able to understand and comply with the requirements of the study, as judged by the Investigator
12. Able to swallow and retain orally administered study treatment and willing to record daily adherence to study treatment
13. Haematological function as follows:
• Absolute neutrophil count greater than or equal to 1.5 x 109/L
• Platelet count greater than or equal to 100 x 109/L
• Haemoglobin (Hb) > 90 g/L
• Prothrombin time (PT) or partial thromboplastin time (PTT) < 1.5 x upper limit of normal (ULN)
14. Renal function as follows: Serum creatinine less than or equal to 1.5 x ULN or calculated creatinine clearance greater than or equal to 40 ml/min using the Cockcroft-Gault formula
15. Hepatic function as follows:
• Total bilirubin less than or equal to 1.5 x ULN (Exception: Patient has known or suspected Gilbert’s Syndrome for which additional lab testing of direct and/or indirect bilirubin supports this diagnosis. In these instances, a total bilirubin of less than or equal to 3.0 x ULN is acceptable)
• Alkaline phosphatase (ALP) less than or equal to 2.5 x ULN
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 x ULN
• Serum albumin greater than or equal to 25 g/L
16. Adequate cardiac function, as follows: Mean resting QTcF interval <470 msec, obtained from triplicate ECGs performed at Screening
17. Negative human immunodeficiency virus (HIV) test at Screening
18. Negative hepatitis B surface antigen (HbsAg) test at Screening Note: Patients who are HbsAg positive due to prior hepatitis B vaccination and have no evidence of active infection are eligible
19. Negative hepatitis C antibody (anti-HCV) test at Screening
20. Women of childbearing potential (WCBP) must agree to use a combination of a hormonal and a non-hormonal contraceptive method or a non-hormonal contraception method alone that is highly effective (with a failure rate of < 1% per year) during study treatment and for at least 1 month following the last dose of study drug and agree not to donate eggs (ova, oocytes) for the purpose of reproduction for the same time period. Note: WCBP are not permitted to use hormonal contraceptive methods alone as a highly effective method of contraception
21. Sexually active male patients must use a condom during intercourse and must agree to refrain from sperm donation, from registration on the study until 1 month after the last dose of treatment
22. Women of childbearing potential must have a negative highly sensitive serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 72 hours prior to registration
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Multicentric / multifocal tumour in which safe maximal resection is not feasible
2. Tumour involves cerebellum, brainstem, or deep basal ganglia
3. Contraindication to surgery
4. Prior neurosurgical biopsy or resection within 28 days prior to registration
5. Patients who require urgent resection for mass effect, cerebral oedema, or hydrocephalus in the opinion of the treating neurosurgeon
6. Evidence of acute intracranial/intra-tumoural haemorrhage, which requires urgent intervention
7. History of CNS bleeding as defined by stroke or arterial thrombosis (e.g., stroke or transient ischaemic attack) within 6 months prior to registration
8. Patients with contraindications to MRI or unwilling to undergo MRI
9. Prior treatment with MATA2 inhibitor or a PRMT5 inhibitor
10. Prior treatment with bevacizumab or immunotherapy. Note: Patients who have received lomustine are eligible
11. Administration of any non-cytotoxic potential anti-tumour agent and or herbal preparation/medications within 7 days of planned biopsy
12. Use of therapeutic anticoagulation. Note: Prophylactic low molecular weight heparins and low dose aspirin is allowed
13. Treatment with immunosuppressive medications. Note: Low-dose corticosteroids (less than or equal to 2 mg/day dexamethasone or equivalent) for tumour-associated oedema is permitted. Patients who require corticosteroids > 2 mg/day dexamethasone (or equivalent) for acute emergencies during the screening window will be eligible if the corticosteroid dosing reduces to less than or equal to 2 mg/day dexamethasone (or equivalent) at least one day prior to the initial trial-mandated biopsy
14. Ongoing need for a medication known as a strong inhibitor or strong inducer of CYP3A4 and/or P-glycoprotein (P-gp) or a proton-pump inhibitor that cannot be switched to alternative treatment prior to registration. The following drug interaction databases and other literature can be utilised to determine the CYP3A4/P-gp inhibitors and inducers: https://www.fda.gov/drugs/drug-interactions-labeling/drugdevelopment-and-druginteractions-table-substratesinhibitors-and-inducers; https://druginteractions.medicine.iu.edu/MainTable.aspxhttps://druginteractions.medicine.iu.edu/MainTable.aspx.
15. Ongoing need for a medication with a known risk of Torsades de Pointes that cannot be switched to alternative treatment prior to registration
16. Significant cardiac dysfunction defined as:
• Unstable angina pectoris or myocardial infarction within 6 months prior to registration
• Congestive heart failure greater than or equal to New York Heart Association Class 3 within 6 months prior to registration
• Left ventricular ejection fraction (LVEF) < 50%
• Prolonged QTc > 470 milliseconds or medical or immediate family history of congenital Long QT Syndrome
• Symptomatic or uncontrolled atrial fibrillation or other arrhythmia within 6 months prior to registration
17. Gastrointestinal tract disease causing inability to take oral medication, malabsorption syndrome, gastric/jejunal tube feeds, uncontrolled inflammatory GI disease (e.g., Crohn’s disease, ulcerative colitis)
18. Active tuberculosis
19. Severe infection within 4 weeks prior to registration. A severe infection is defined as an infection that leads to septic shock, organ dysfunction, or admission to intensive care within four weeks of a patient's registration. It also includes any active, uncontrolled infection, such as fungemia or bacteraemia
20. Treatment with a live, attenuated vaccine within 4 weeks prior to registration, or anticipation of need for such a vaccine during the study
21. Patients are excluded if they have had another malignancy or received treatment for another malignancy within two years of enrolment. The only exceptions are patients with adequately treated cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin. Patients with a history of other malignancies are eligible if they have been treated with curative intent or continuously disease free for at least 2 years after definitive primary treatment
22. Major surgical procedure, within 4 weeks prior to registration
23. History of idiopathic pulmonary fibrosis, organising pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
24. Patient is pregnant or breast-feeding
25. Known severe hypersensitivity to study treatment and/or any of its excipients
26. Prior allogeneic stem cell or solid organ transplantation
27. Presence of any psychological, social, geographical, or other condition for which, in the opinion of the site Investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 28675 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment postcode(s) [1] 44908 0
3000 - Melbourne

Funding & Sponsors
Funding source category [1] 320267 0
Government body
Name [1] 320267 0
Victorian Government
Country [1] 320267 0
Australia
Primary sponsor type
Hospital
Name
Peter MacCallum Cancer Centre
Address
Country
Australia
Secondary sponsor category [1] 322833 0
None
Name [1] 322833 0
Address [1] 322833 0
Country [1] 322833 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 318809 0
Peter MacCallum Cancer Centre Human Research Ethics Committee
Ethics committee address [1] 318809 0
Ethics committee country [1] 318809 0
Australia
Date submitted for ethics approval [1] 318809 0
08/08/2025
Approval date [1] 318809 0
31/10/2025
Ethics approval number [1] 318809 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 145330 0
Dr James Whittle
Address 145330 0
Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne VIC 3000
Country 145330 0
Australia
Phone 145330 0
+61 3 8559 5000
Fax 145330 0
Email 145330 0
Contact person for public queries
Name 145331 0
James Whittle
Address 145331 0
Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne VIC 3000
Country 145331 0
Australia
Phone 145331 0
+61 3 8559 5000
Fax 145331 0
Email 145331 0
Contact person for scientific queries
Name 145332 0
James Whittle
Address 145332 0
Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne VIC 3000
Country 145332 0
Australia
Phone 145332 0
+61 3 8559 5000
Fax 145332 0
Email 145332 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.